AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23878115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (500-1500 mg/day) + Docetaxel (triweekly; 60-100 mg/m²) + Trastuzumab (weekly; 2 mg/kg fixed dose)
Number of subjects: 53
Study 23878115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib/docetaxel/trastuzumab
Number of subjects: 53
Study 23878115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib/docetaxel
Number of subjects: 53
Study 23878115 — intervention group
Group type: EXPERIMENTAL
Intervention: Common adverse events
Number of subjects: 53
Study 23878140 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT3 N676K mutation
Number of subjects: 120
Study 23878140 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT3 N676K mutation with concurrent FLT3-ITD
Number of subjects: 120
Study 23878140 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression analysis
Number of subjects: 120
Study 23878179 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoE6
Number of subjects: 7543
Study 23878179 — intervention group
Group type: EXPERIMENTAL
Intervention: careHPV (clinician-collected specimen)
Number of subjects: 7543
Study 23878179 — intervention group
Group type: EXPERIMENTAL
Intervention: HC2 (clinician-collected specimen)
Number of subjects: 7543
Study 23878179 — intervention group
Group type: EXPERIMENTAL
Intervention: careHPV (self-collected specimen)
Number of subjects: 7543
Study 23878179 — intervention group
Group type: EXPERIMENTAL
Intervention: HC2 (self-collected specimen)
Number of subjects: 7543
Study 23878179 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA
Number of subjects: 7543
Study 23878179 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV E6 oncoprotein
Number of subjects: 7543
Study 23878179 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-HPV DNA testing
Number of subjects: 7543
Study 23879405 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib (2 x 400 mg/day orally) and pegylated interferon alpha-2b (3 μg/kg body weight 1 x/week subcutaneously)
Number of subjects: 55
Study 23880820 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP02 (MM-398) 120 mg/m(-2) intravenous injection every 3 weeks
Number of subjects: 40
Study 23881401 — intervention group
Group type: EXPERIMENTAL
Intervention: Proceed™ Ventral Patch (PVP™)
Number of subjects: 101
Study 23881779 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI (Pulmonary Vein Isolation)
Number of subjects: 30
Study 23881779 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear lesions (roof and mitral isthmus)
Number of subjects: 30
Study 23881779 — intervention group
Group type: EXPERIMENTAL
Intervention: LA ablation
Number of subjects: 30
Study 23881779 — intervention group
Group type: EXPERIMENTAL
Intervention: Single procedure
Number of subjects: 30
Study 23881779 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete linear lesion block
Number of subjects: 30
Study 23882105 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind nasotracheal suctioning and non-bronchoscopic mini-BAL
Number of subjects: 36
Study 23882105 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bronchoscopic mini-BAL
Number of subjects: 36
Study 23882105 — intervention group
Group type: COMPARATOR
Intervention: Expectorated sputum
Number of subjects: 36
Study 23882105 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind nasotracheal suctioning
Number of subjects: 36
Study 23883872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tigecycline (100 mg for 30 min)
Number of subjects: 12
Study 23883891 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a Smartphone with the MONARCA application
Number of subjects: 78
Study 23883891 — intervention group
Group type: COMPARATOR
Intervention: Use of a cell phone without the application (placebo group)
Number of subjects: 78
Study 23884778 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week supervised aerobic exercise training program
Number of subjects: 0
Study 23885047 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected serum ferritin (SF) concentrations
Number of subjects: 811
Study 23885047 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected serum ferritin (SF) concentrations
Number of subjects: 811
Study 23885047 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction factor of SF for inflammation
Number of subjects: 811
Study 23885047 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity status (normal, overweight, obese)
Number of subjects: 811
Study 23885047 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation status
Number of subjects: 811
Study 23886346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (50 mg for 2 weeks, 100 mg for 6 weeks)
Number of subjects: 45
Study 23886346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 23886402 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 2874
Study 23886836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 23887072 — intervention group
Group type: EXPERIMENTAL
Intervention: High mitochondrial DNA (mtDNA) concentration in embryo culture medium
Number of subjects: 800
Study 23887072 — intervention group
Group type: COMPARATOR
Intervention: Low mitochondrial DNA (mtDNA) concentration in embryo culture medium
Number of subjects: 800
Study 23887359 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum uric acid levels
Number of subjects: 91
Study 23887359 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid
Number of subjects: 91
Study 23887359 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA
Number of subjects: 91
Study 23887359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C reactive protein (CRP)
Number of subjects: 91
Study 23887359 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR)
Number of subjects: 91
Study 23887595 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh reinforcement
Number of subjects: 4786
Study 23887595 — intervention group
Group type: COMPARATOR
Intervention: Sutured repair
Number of subjects: 4786
Study 23887595 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both interventions)
Number of subjects: 4786
Study 23887802 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic fundus reflex photographs
Number of subjects: 777
Study 23887802 — intervention group
Group type: COMPARATOR
Intervention: Film-based retroillumination images
Number of subjects: 777
Study 23887852 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg twice daily and Bortezomib 1.3 mg/m2 on days 1, 4, 8, 11 (21-day cycles)
Number of subjects: 14
Study 23887852 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg twice daily and Bortezomib 1 mg/m2 on days 1, 4, 8, 11 (21-day cycles)
Number of subjects: 14
Study 23890349 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein intake (0.98 ± 0.28 g/kg body weight in males; 0.95 ± 0.29 g/kg body weight in females)
Number of subjects: 237
Study 23890349 — intervention group
Group type: COMPARATOR
Intervention: Leisure-time physical activity (predominantly endurance type exercises)
Number of subjects: 237
Study 23890523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 0.5mg/day continuously
Number of subjects: 50
Study 23890523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 3.0mg/day
Number of subjects: 50
Study 23890766 — intervention group
Group type: EXPERIMENTAL
Intervention: GINA
Number of subjects: 99
Study 23890766 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Control Test™
Number of subjects: 99
Study 23890766 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal College of Physician score
Number of subjects: 99
Study 23890766 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Therapy Assessment Questionnaire (ATAQ)
Number of subjects: 99
Study 23890766 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Control Questionnaire (ACQ)
Number of subjects: 99
Study 23890998 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet reactivity on clopidogrel
Number of subjects: 8583
Study 23890998 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet reactivity on aspirin
Number of subjects: 8583
Study 23890998 — intervention group
Group type: COMPARATOR
Intervention: Overall clinical outcomes
Number of subjects: 8583
Study 23891066 — intervention group
Group type: EXPERIMENTAL
Intervention: e-health platform with personalized care plan delivered via iPads
Number of subjects: 149
Study 23891066 — intervention group
Group type: EXPERIMENTAL
Intervention: e-health platform with personalized care plan
Number of subjects: 149
Study 23891131 — intervention group
Group type: EXPERIMENTAL
Intervention: Air pollution exposure
Number of subjects: 0
Study 23891131 — intervention group
Group type: COMPARATOR
Intervention: Standard care for acute coronary syndrome
Number of subjects: 0
Study 23891361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (in addition to aspirin)
Number of subjects: 0
Study 23891361 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (in addition to aspirin)
Number of subjects: 0
Study 23891361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 23891361 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 23891361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor compared with Clopidogrel
Number of subjects: 0
Study 23891588 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic mastectomy
Number of subjects: 0
Study 23891588 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23891891 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous vaginal delivery (n=24; 12 male, 12 female)
Number of subjects: 48
Study 23891891 — intervention group
Group type: COMPARATOR
Intervention: Elective caesarean section (n=24; 12 male, 12 female)
Number of subjects: 48
Study 23892385 — intervention group
Group type: EXPERIMENTAL
Intervention: LA expansion index
Number of subjects: 2200
Study 23892385 — intervention group
Group type: EXPERIMENTAL
Intervention: LA expansion index <61.4%
Number of subjects: 2200
Study 23892551 — intervention group
Group type: COMPARATOR
Intervention: Pattern electroretinogram (PERG) measurements in NMO and MS + ON eyes
Number of subjects: 92
Study 23892551 — intervention group
Group type: COMPARATOR
Intervention: Pattern electroretinogram (PERG) measurements in MS - ON eyes
Number of subjects: 92
Study 23892551 — intervention group
Group type: COMPARATOR
Intervention: PERG and OCT performance
Number of subjects: 92
Study 23892551 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of N95 amplitude values
Number of subjects: 92
Study 23892551 — intervention group
Group type: EXPERIMENTAL
Intervention: PERG amplitude
Number of subjects: 92
Study 23892551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern electroretinogram measurements
Number of subjects: 92
Study 23892551 — intervention group
Group type: EXPERIMENTAL
Intervention: PERG amplitude measurements
Number of subjects: 92
Study 23892959 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7762 monotherapy (6 mg, 9 mg, 21 mg, 30 mg)
Number of subjects: 20
Study 23892959 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7762 plus gemcitabine (1,000 mg/m2)
Number of subjects: 20
Study 23892959 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7762 monotherapy
Number of subjects: 20
Study 23892959 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7762 (all doses)
Number of subjects: 20
Study 23893090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis) 0.5 mg/0.05 ml injections
Number of subjects: 20
Study 23893090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis) injections
Number of subjects: 20
Study 23893303 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (RYGB)
Number of subjects: 0
Study 23894304 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 50 mg/m(2)/day for 5 days combined with vincristine 1.5 mg/m(2) on days 1 and 8, temozolomide 100 mg/m(2) on days 1-5, and bevacizumab 15 mg/kg on day 1, administered every 21 days for a maximum of 12 cycles
Number of subjects: 13
Study 23894304 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 50 mg/m(2)/day for 5 days
Number of subjects: 13
Study 23895556 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial affect recognition tests
Number of subjects: 75
Study 23895556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive test battery assessing seven cognitive domains
Number of subjects: 75
Study 23895556 — intervention group
Group type: COMPARATOR
Intervention: Executive dysfunction
Number of subjects: 75
Study 23895940 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 307
Study 23896965 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (12.5, 25, or 50 mg once daily)
Number of subjects: 19
Study 23897705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with gemcitabine
Number of subjects: 76
Study 23897961 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-based induction
Number of subjects: 1572
Study 23897961 — intervention group
Group type: COMPARATOR
Intervention: Nonbortezomib-based induction
Number of subjects: 1572
Study 23898205 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy
Number of subjects: 0
Study 23898205 — intervention group
Group type: COMPARATOR
Intervention: MMA renal disease model (Mut(-/-);Tg(INS-Alb-Mut) mice)
Number of subjects: 0
Study 23898383 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMCs from IBS children cultured with 5 ng/mL LPS
Number of subjects: 94
Study 23898383 — intervention group
Group type: COMPARATOR
Intervention: PBMCs from healthy controls (HCs) cultured with 5 ng/mL LPS
Number of subjects: 94
Study 23899210 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent Exacerbators (IE)
Number of subjects: 1832
Study 23899210 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent Exacerbators (FE)
Number of subjects: 1832
Study 23899210 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe disease
Number of subjects: 1832
Study 23899210 — intervention group
Group type: EXPERIMENTAL
Intervention: Less severe disease
Number of subjects: 1832
Study 23899210 — intervention group
Group type: EXPERIMENTAL
Intervention: Small falls in FEV1 and 6-minute walking distance
Number of subjects: 1832
Study 23899210 — intervention group
Group type: EXPERIMENTAL
Intervention: Small falls in platelet count
Number of subjects: 1832
Study 23899210 — intervention group
Group type: EXPERIMENTAL
Intervention: No specific parameter
Number of subjects: 1832
Study 23899439 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG 50 mg daily for 5-7 days
Number of subjects: 8
Study 23899517 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus vaccine (NMRC-M3V-Ad-PfCA)
Number of subjects: 18
Study 23899969 — intervention group
Group type: EXPERIMENTAL
Intervention: BRADA questionnaire
Number of subjects: 0
Study 23899969 — intervention group
Group type: COMPARATOR
Intervention: HAQ-DI
Number of subjects: 0
Study 23899969 — intervention group
Group type: COMPARATOR
Intervention: SF-36
Number of subjects: 0
Study 23899969 — intervention group
Group type: COMPARATOR
Intervention: DAS28
Number of subjects: 0
Study 23900207 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse incubator culture till Day 6; measured parameters include duration of the first cytokinesis, duration of the 3-cell stage, and direct cleavage to 3-cells.
Number of subjects: 92
Study 23900207 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse incubator culture till Day 6; measured timing of development.
Number of subjects: 92
Study 23900652 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (BF) alone or in combination with electrical stimulation (ES)
Number of subjects: 13
Study 23900652 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude-modulated medium-frequency (AM-MF) stimulation combined with biofeedback (BF)
Number of subjects: 13
Study 23900652 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback (BF)
Number of subjects: 13
Study 23900652 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback (BF) plus electrical stimulation (ES)
Number of subjects: 13
Study 23900652 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency electrical stimulation (ES)
Number of subjects: 13
Study 23900652 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude-modulated medium-frequency electrical stimulation (AM-MF ES) plus electromyography biofeedback (BF)
Number of subjects: 13
Study 23900696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 3782
Study 23900696 — intervention group
Group type: COMPARATOR
Intervention: No active device or defibrillator (Control)
Number of subjects: 3782
Study 23901027 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive preventive health record (IPHR) users
Number of subjects: 28
Study 23901027 — intervention group
Group type: COMPARATOR
Intervention: Non-users of the IPHR
Number of subjects: 28
Study 23901030 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture (TA)
Number of subjects: 200
Study 23901030 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 200
Study 23901077 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine delivered on alternative dosing schedules (0, 3, 9 months; 0, 6, 12 months; or 0, 12, 24 months)
Number of subjects: 0
Study 23901077 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine delivered on the 0, 12, 24 month schedule
Number of subjects: 0
Study 23901077 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine delivered on any of the alternative dosing schedules
Number of subjects: 0
Study 23901077 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of HPV vaccine delivered at 0 and 12 months
Number of subjects: 0
Study 23902316 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month individualized dietary intervention aimed at achieving a 5-10% weight loss
Number of subjects: 47
Study 23902316 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 nonoverweight volunteers)
Number of subjects: 47
Study 23902316 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month individualized dietary intervention
Number of subjects: 47
Study 23903369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (90/30 mg/day, split dose) for 3 weeks
Number of subjects: 27
Study 23903369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (90/30 mg/day, split dose)
Number of subjects: 27
Study 23903897 — intervention group
Group type: EXPERIMENTAL
Intervention: Icrucumab (2-12 mg/kg weekly, 15 mg/kg every other week, 20 mg/kg every third week)
Number of subjects: 26
Study 23904461 — intervention group
Group type: EXPERIMENTAL
Intervention: TriMixDC-MEL (intravenous synthetic mRNA electroporated dendritic cell immunotherapy)
Number of subjects: 15
Study 23905567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist recommendations for medical patients
Number of subjects: 301
Study 23905567 — intervention group
Group type: COMPARATOR
Intervention: Pharmacist recommendations for surgical patients
Number of subjects: 301
Study 23905567 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations of significant or vital importance for medical patients
Number of subjects: 301
Study 23905567 — intervention group
Group type: COMPARATOR
Intervention: Recommendations of significant or vital importance for surgical patients
Number of subjects: 301
Study 23905663 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (n = 30)
Number of subjects: 119
Study 23905663 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (n = 30)
Number of subjects: 119
Study 23905663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of strength training and endurance training (n = 30)
Number of subjects: 119
Study 23905663 — intervention group
Group type: EXPERIMENTAL
Intervention: Careful treatment including diet and physical recommendations (n = 29)
Number of subjects: 119
Study 23905663 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 119
Study 23906960 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Concussion Symptom Inventory, a validated tool in children as young as 5 years, followed at 1, 2, 4, 8 and 12 weeks postinjury.
Number of subjects: 1792
Study 23907406 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (75 mg/m² for 5 days), Valproic Acid (20 mg/kg for 7 days), Carboplatin (AUC 3.0 starting in second cycle)
Number of subjects: 32
Study 23907406 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine, Valproic Acid, and Carboplatin
Number of subjects: 32
Study 23907471 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical worsening (defined as worsening functional class, a ≥ 15% reduction in 6-min walk distance, all-cause hospitalization, or introduction of parenteral prostacyclin analog therapy)
Number of subjects: 3001
Study 23907471 — intervention group
Group type: COMPARATOR
Intervention: No clinical worsening
Number of subjects: 3001
Study 23907497 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESERVE score (0-14 points) based on eight pre-ECMO parameters
Number of subjects: 140
Study 23907497 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQL evaluation in 80% of the 6-month survivors
Number of subjects: 140
Study 23907731 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum B-type natriuretic peptide (BNP) test with a cutoff of >364 pg/mL
Number of subjects: 218
Study 23907731 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum B-type natriuretic peptide (BNP) test with a cutoff of ≤ 182 pg/mL
Number of subjects: 218
Study 23907731 — intervention group
Group type: COMPARATOR
Intervention: Serum-ascites albumin gradient (SAAG) and total protein concentration in ascites
Number of subjects: 218
Study 23907766 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposome injection (VSLI) at a maximum tolerated dose of 2.25 mg/m² once per week without a dose cap
Number of subjects: 0
Study 23907766 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposome injection (VSLI)
Number of subjects: 0
Study 23908066 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire Flow Restoration Thrombectomy
Number of subjects: 202
Study 23908179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone spacing measures
Number of subjects: 26
Study 23908179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone density measures
Number of subjects: 26